IN THE UNITED STATES DISTRICT COURT

KELLYN CLAY,
  Plaintiff,

v.

UNITED STATES OF AMERICA,
by and through its agencies including but not limited to
the Central Intelligence Agency (CIA), Department of Defense (DoD),
and Department of Justice (DOJ),

and

WILLIAM ALTON CLAY,
individually and in his capacity as executor of the Estate of Eugenia Clay Head,

and

PALANTIR TECHNOLOGIES INC.,
a private defense contractor headquartered in Denver, Colorado,

and

JOHN DOE CONTRACTING AGENCIES AND AFFILIATES,
whose names and identities are presently unknown,

and

AMAZON.COM, INC.,
a multinational e-commerce corporation headquartered in Seattle, Washington,

and

REV.COM, INC.,
a transcription and captioning services company headquartered in Austin, Texas,

and

PAPERBOY MARKETING,
a flyer distribution company operating in the Twin Cities under successive ownership during the period of Plaintiff’s employment,

and

ELLIE FAMILY SERVICES, n/k/a ELLIE MENTAL HEALTH, a private mental health services corporation headquartered in Mendota Heights, Minnesota,
  Defendants.

⸻ 

PLAINTIFF’S TWELFTH SET OF DISCOVERY REQUESTS TO DEFENDANT PALANTIR TECHNOLOGIES

Plaintiff: Kellyn Clay
Defendant: Palantir Technologies Inc.
Subject Matter: Moderna Covid-19 Vaccine Lot Numbers Administered to Plaintiff

⸻

INTERROGATORIES
	1.	Identify all datasets, records, or anomaly detection modules in which Palantir processed data related to the two specific Moderna vaccine lot numbers administered to Plaintiff.
	2.	Identify whether Palantir classified either of Plaintiff’s Moderna vaccine lot numbers as contaminated, anomalous, or otherwise requiring heightened monitoring.
	3.	Identify all Palantir personnel, contractors, or teams who accessed, analyzed, or reported on Plaintiff’s Moderna lot numbers.
	4.	Identify whether Palantir linked data concerning Plaintiff’s Moderna lot numbers to adverse events, anomaly detection, or digital twin modeling of Plaintiff.
	5.	Identify all government agencies (CDC, FDA, DoD, HHS, etc.) with whom Palantir shared analytics concerning Plaintiff’s Moderna lot numbers.

⸻

REQUESTS FOR PRODUCTION
	1.	Produce all records, anomaly flags, or analytic reports concerning Plaintiff’s two Moderna vaccine lot numbers.
	2.	Produce all internal Palantir communications, reports, or memoranda referencing Plaintiff’s Moderna lot numbers.
	3.	Produce all records showing whether Plaintiff’s lot numbers were flagged for contamination, misformulation, or abnormal adverse event patterns.
	4.	Produce all communications between Palantir and government agencies concerning Plaintiff’s Moderna lot numbers.
	5.	Produce all records linking Plaintiff’s Moderna lot numbers to behavioral futures transactions, anomaly markets, or predictive modeling.

⸻

REQUESTS FOR ADMISSION
	1.	Admit that Palantir ingested data concerning Plaintiff’s two Moderna vaccine lot numbers.
	2.	Admit that Palantir flagged one or both of Plaintiff’s Moderna lot numbers as contaminated or anomalous.
	3.	Admit that Palantir linked Plaintiff’s adverse event reports to the lot numbers administered.
	4.	Admit that Palantir communicated with government agencies about Plaintiff’s Moderna lot numbers.
	5.	Admit that Palantir has not disclosed to Plaintiff the scope of its data processing concerning Plaintiff’s Moderna lot numbers.

⸻ 

Respectfully submitted,
Kellyn Clay, Plaintiff, pro se 
